论文部分内容阅读
心磷脂(cardiolipin,CL)是线粒体内膜的特征性磷脂,参与线粒体嵴的形成。心磷脂在线粒体内的合成伴随着特殊的分子重构过程,从而使其自身的4条酰基链形成特定的组成,以发挥其特殊的生理功能。研究发现,心磷脂重构对维持线粒体的形态及功能至关重要,其重构异常是大多数心血管疾病(cardiovascular disease,CVD)共有的病理现象,相应的分子机制研究得到了广泛关注。本文主要对心磷脂的理化特性及其生物合成途径,以及心磷脂重构在巴氏综合征(Barth syndrome,BTHS)、糖尿病心肌病(diabetic cardiomyopathy,DCM)以及心力衰竭(heart failure,HF)等心血管疾病的病理生理过程研究中的进展进行综述,以期为与心磷脂重构相关的心血管疾病的病理生理基础研究和药物干预的分子机制研究提供参考。
Cardiolipin (cardiolipin, CL) is a characteristic phospholipid of the mitochondrial inner membrane, involved in the formation of mitochondrial cristae. The synthesis of cardiolipin in the mitochondria is accompanied by a special molecular remodeling process, so that its own four acyl chains to form a specific composition to play its special physiological functions. It has been found that cardiolipin remodeling plays an important role in maintaining the morphology and function of mitochondria. The remodeling abnormality is a common pathological phenomenon in most cardiovascular diseases (CVD). Corresponding molecular mechanisms have drawn much attention. In this paper, the physicochemical properties of cardiolipin and its biosynthetic pathway, as well as the reconstruction of cardiolipin in Barth syndrome, diabetic cardiomyopathy (DCM) and heart failure (HF) The progress in the pathophysiological process of cardiovascular diseases is reviewed in order to provide a reference for the basic research of pathophysiology and the molecular mechanism of drug intervention in the cardiovascular diseases related to cardiolipin remodeling.